Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03717012 · ClinicalTrials.gov registry record · Phase 4
Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 4 study, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- Phase 4
- Development phase
- 19
- Enrollment target
NCT03717012 is a Phase 4 study that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 19 participants.
The verdict
NCT03717012, a Phase 4 study, was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 19 participants
- Enrollment target
Study Summary
The main objectives of this study are: * Determine the difference in change from baseline in Six Minute Walk Distance (6MWD) when pulmonary rehabilitation (PR) is added to stable underlying nintedanib therapy in patients with idiopathic pulmonary fibrosis (IPF) * Determine the difference in change in Quality of Life (QoL) when pulmonary rehabilitation (PR) is added to stable underlying nintedanib therapy in patients with idiopathic pulmonary fibrosis (IPF) * Determine if there is an enduring effect in 6MWD, QoL and lung function from pulmonary rehabilitation (PR) when pulmonary rehabilitation (PR) is added to stable underlying nintedanib therapy in patients with idiopathic pulmonary fibrosis (IPF)
Interventions
- DRUG Nintedanib
- OTHER Pulmonary rehabilitation program
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-11-15 |
| Est. Completion | 2020-06-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03717012
The ClinicalTrials.gov registry entry for NCT03717012 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nintedanib is the first listed.
NCT03717012 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03717012 about?
NCT03717012 is a clinical study titled "Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF)". The main objectives of this study are: * Determine the difference in change from baseline in Six Minute Walk Distance (6MWD) when pulmonary rehabilitation (PR) is added to stable underlying nintedanib therapy in patients with idiopathic pulmonary fibrosis (IPF) * Determine the difference in change ...
What is the current status of trial NCT03717012?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 19 participants. The study started on 2018-11-15. Estimated completion is 2020-06-10.
What interventions are being tested in trial NCT03717012?
The interventions under investigation include: Nintedanib (DRUG), Pulmonary rehabilitation program (OTHER).
Who is sponsoring clinical trial NCT03717012?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.